New antibody combo targets Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…
Phase: PHASE1 • Sponsor: Zumutor Biologics Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC